Celltrion Inc. Has Completed a Large-Scale Global Phase III Trial of Its Investigational COVID19 Drug Rekirona (Regdanvimab), Pushing The Antibody Treatment One Step Closer to Global Launch, The Korean Biopharma Company Said on Monday .